Let’s Talk Contraception: The One-Size Diaphragm, a New Contraceptive

SILCS diaphragmIn June of 2013, a new barrier contraceptive, the SILCS diaphragm, entered the market in Europe, and in May of this year, it became available in Canada. The new diaphragm is called the Caya contoured diaphragm, and it’s being marketed as “not your mother’s diaphragm.” This is exciting because Caya is a user-friendly, one-size diaphragm that can fit most users without the need of a pelvic exam. It is being sold through pharmacies and health care providers.


An over-the-counter, one-size-fits-most diaphragm could be available in U.S. pharmacies as early as next year.


The SILCS diaphragm was developed with the financial help of the U.S. Agency for International Development (USAID), by CONRAD and PATH, nonprofit leaders in global contraceptive research. USAID was created in 1961 by President Kennedy, and provides financial support to improving the lives of people in developing countries, including support to find safe, effective, and acceptable contraceptives in low-resource areas. CONRAD began in 1986 as a division of the obstetrics and gynecology department of East Virginia Medical School in Norfolk, Virginia, and collaborates on research to improve reproductive health around the world. PATH is a Seattle-based international nonprofit that works globally to develop and deliver health solutions that are affordable and effective, including vaccines, drugs, and medical devices.

Caya works as well as traditional diaphragms, but has been redesigned to make it easier to insert and remove. During its development, many women, their partners, and health-care providers on four continents had input on its design. Continue reading

Let’s Talk Contraception: New Contraceptives and HIV Protection

This ring, currently under development, can be inserted into the vagina to prevent both pregnancy and HIV transmission. Image: USAID

This ring, currently under development, might reduce risk for both pregnancy and HIV transmission. Image: USAID

The World Health Organization estimated that in 2012 there were 35.3 million people worldwide living with HIV. A whopping 69 percent of them live in sub-Saharan Africa. Save the Children reports that 2 out of 5 children born in developing countries are the result of unintended pregnancies.

Condoms remain the gold standard for protection against HIV transmission. But not all women are able to negotiate condom use. The same can be said for contraceptives. Health-care providers in some areas of the world are not even able to provide condoms consistently due to political or financial pressures.


An intravaginal ring under development might protect against pregnancy, HIV, and genital herpes.


But there are nonprofit groups researching and developing products to meet the needs of women in these countries. With the financial backing of the U.S. Agency for International Development (USAID), CONRAD, a nonprofit committed to improving reproductive health globally, is testing a new intravaginal ring that combines a hormonal contraceptive, levonorgestrel, and an HIV microbicide, tenofovir, in the same product. When inserted vaginally, it slowly dispenses both drugs to prevent pregnancy and HIV transmission. Continue reading